Pembrolizumab can improve outcomes in patients with metastatic melanoma
A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published today in the journal JAMA Oncology provides new insights into an important question.
.png)
No hay comentarios:
Publicar un comentario